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s u m m a r y 
Objectives: To summarize the available evidence on the diagnostic performance for invasive aspergillo- 
sis (IA) in non-hematological, non-solid organ transplantation critically ill patients of the following: ( i ) 
existing definitions of IA (developed either for classical immunocompromised populations or for non- 
immunocompromised critically ill patients); ( ii ) laboratory tests; ( iii ) radiology tests. 
Methods: A systematic review was performed by evaluating studies assessing the diagnostic performance 
for IA of a definition/s and/or laboratory/radiology test/s vs. a reference standard (histology) or a reference 
definition. 
Results: Sufficient data for evaluating the performance of existing definitions and laboratory tests for 
the diagnosis of IA in critically ill patients is available only for invasive pulmonary aspergillosis. Against 
histology/autopsy as reference, the AspICU definition showed a promising diagnostic performance but 
based on small samples and applicable only to patients with positive respiratory cultures. Studies on 
laboratory tests consistently indicated a better diagnostic performance of bronchoalveolar lavage fluid 
(BALF) galactomannan (GM) than serum GM, and a suboptimal specificity of BALF and serum (1,3)- β- D - 
glucan. 
Conclusions: Evidence stemming from this systematic review will guide the discussion for defining inva- 
sive aspergillosis within the FUNDICU project. The project aims to develop a standard set of definitions 
for invasive fungal diseases in critically ill, adult patients. 
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Invasive aspergillosis (IA) is a severe invasive fungal disease
IFD) that usually affects but is not limited to immunocompro-
ised patients. 1–4 In non-immunocompromised critically ill pa-
ients, IA is often difficult to diagnose for the following reasons:
 i ) proven (histological) diagnosis is rarely available; ( ii ) it may
evelop in patients without the classical host factors of hemato-
ogical and solid organ transplantation (SOT) patients and without
he classical radiologic features described in immunocompromised
atients; ( iii ) diagnostic techniques based on non-culture meth-
ds such as galactomannan detection or DNA amplification exhibit
 lower performance in non-neutropenic patients. 5–8 To address
hese limitations, some definitions of IA in intensive care unit (ICU)
atients have been proposed. 9–11 However, their application botheserved. 

































































































d  in clinical practice and in research is not based on broad consen-
sus, and whether they can be generalized to all critically ill pa-
tients remains unknown. 
In this systematic review, we summarized the available evi-
dence on the diagnostic performance (for the diagnosis of IA in
non-hematological, non-SOT critically ill patients) of the follow-
ing: ( i ) existing definitions of IA (developed either for classical im-
munocompromised populations or for non-immunocompromised
critically ill patients); ( ii ) laboratory tests; ( iii ) radiology tests. The
present qualitative summary will guide the discussion across the
expert panel of the FUNgal infections Definitions in ICU patients
(FUNDICU) project. 12 The FUNDICU project aims to develop a stan-
dard set of definitions for IFD in critically ill, adult patients, start-
ing from a systematic assessment of the strengths and limitations
of definitions and clinical/laboratory algorithms already available
in the literature. Other qualitative syntheses to guide the develop-
ment of definitions for invasive candidiasis and other IFD in this
population are also being prepared. 12 
Methods 
This study follows the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) guidelines. 13 The full
FUNDICU protocol has been published in 2018 12 (see Supplemen-
tary material for details). 
Data sources and data management 
We searched PubMed and EMBASE (OvidSP), CINAHL (EBSCO-
Host), and the Cochrane Database (Wiley) using a pre-defined
search string (available in supplementary material). The search pe-
riod was 2003–2018 (15 years). All abstracts and full texts were
imported and managed into an EndNote Web database, and shared
between CG, DRG, VZ and the librarian (CR). Abstract and full text
review was performed independently by CG and VZ. References of
retrieved full texts were also screened to identify further studies
suitable for inclusions. Finally, independent decisions on inclusion
were compared between CG and VZ, with disagreement being re-
solved by a third reviewer (DRG). 
Inclusion and exclusion criteria 
We included cross-sectional studies, longitudinal (cohort)
prospective or retrospective studies, randomized controlled tri-
als, single-arm studies, quasi-experimental studies that assessed
the diagnostic performance for IA of a definition/s and/or labora-
tory/radiology test/s vs. a reference standard (histology) or a refer-
ence definition. 
Studies were excluded if: ( i ) they were conducted exclusively
in the pediatric population ( < 18 years) ( ii ) the diagnostic perfor-
mance of tests/definitions for IA cannot be separated from the di-
agnostic performance for other IFD considered in the given study;
( iii ) patients who were classified in specific reference categories
(e.g., possible IA) were excluded from the analysis of the diagnos-
tic performance of the evaluated test/s or definition/s. We also ex-
cluded those studies in which the population was composed for
≥50% by hematological and/or SOT patients. However, if mixed
populations were present but no information about the proportion
of hematological and/or SOT patients was provided, studies were
retained if it was clearly stated in methods that they involved also
wards other than hematology/SOT (e.g., hematology plus ICU). 
Data extraction 
Data were extracted on a standard form. The form was drafted
by VZ and DRG, with supervision by LS. For each study, the fol-owing data was extracted by VZ and DRG: first author; publica-
ion year; type of study (RCT, observational); study timeline (ret-
ospective, prospective, cross-sectional); site of IA (e.g., pulmonary,
erebral, any); study population; setting (e.g., ICU, other wards);
umber of enrolled patients; reference definition/test applied in
he study; reference diagnostic categories (e.g., IA/non-IA, non-
A/possible IA/probable IA/proven IA) and number of patients clas-
ified in the different reference categories; tests/definitions evalu-
ted in the study; used cut-offs (where applicable); diagnostic per-
ormance of the evaluated tests/definitions with respect to the ref-
rence (sensitivity, specificity, positive predictive value [PPV], nega-
ive predictive value [NPV]; positive likelihood ratio [LR + ], negative
ikelihood ratio [LR-], diagnostic odds ratio [DOR]). 
isk of bias 
The risk of bias in included studies was assessed using a scoring
ool specifically designed for this project. One point was assigned
or each of the following potential sources of bias, with higher total
cores thus corresponding to higher risk of bias: 
• retrospective study 
• missing IFD classification of > 10% of included patients (for loss
of follow-up or other reasons) 
• study population including also hematological and/or SOT pa-
tients 
• exclusion of patients difficult-to-diagnose from the study 
• combination of adults and children 
• ad hoc selection of the cut-off value (where applicable) 
• unreliability of the reference standard (defined as any reference
standard different from histology) 
• classification as IA after knowledge of the result of the refer-
ence standard (where applicable, i.e., when classification of IA
was based upon arbitrary clinical criteria). 
ata synthesis 
No formal data synthesis was applicable to the present system-
tic review. 12 
esults 
From an initial total of 3078 records, we excluded 766 du-
licates and screened the titles and abstracts of the remaining
312 records ( Fig. 1 ). After evaluation for exclusion criteria of the
21 full texts initially deemed as eligible, 19 were eventually re-
ained for qualitative synthesis ( Fig. 1 ). The information extracted
rom the included studies is presented in the following paragraphs,
tratified according to the reference applied and the evaluated def-
nition/test. All included studies refer almost exclusively to invasive
ulmonary aspergillosis (IPA). A description of the existing defini-
ions used in the included studies (either tested for their perfor-
ance or employed as reference) is available in the supplementary
aterial. 
erformance of existing definitions and laboratory tests with 
istology as reference 
The diagnostic performance for IPA of existing definitions or
aboratory tests with histology as reference was evaluated in 3
tudies ( Table 1 ). 9 , 11 , 14 The prevalence of IPA ranged from 36% to
9%. Although all composed by ICU patients, the three studies dif-
ered in terms of inclusion criteria (population), with the main dif-
erence being the inclusion only of patients with an Aspergillus -
ositive respiratory tract culture in the two studies evaluating the
iagnostic performance of definitions and the inclusion of patients
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Fig. 1. Flow diagram of the study selection process. 
Legend: Modified from. 13 SOT, solid organ transplantation. ∗ We excluded studies in which the population was composed for ≥50% by hematological and/or SOT patients (for 


























































r  ith signs and symptoms suggestive of IPA independent of the re-
ults of respiratory cultures in the study evaluating the diagnostic
erformance of laboratory tests. 9 , 11 , 14 
erformance of laboratory tests with existing definitions as reference 
The majority of included studies on the diagnostic perfor-
ance of laboratory tests assessed galactomannan (GM). More in
etail, the diagnostic performance of serum GM was evaluated
n 9 studies, 15–23 partly overlapping with the 9 studies evaluat-
ng the diagnostic performance of GM in bronchoalveolar lavage
uid (BALF) 15 , 16 , 18 , 22–27 ( Table 2 ). For both serum and BALF GM
ssessments, prevalence of IPA (based on the reference) varied
arkedly across studies (2–44% and 5–30%, respectively), depend-
ng on the study population and reference definition employed.
s shown in the table, the most used reference definition was
hat of the European Organization for Research and Treatment of
ancer/Invasive Fungal Infections Cooperative Group and the Na-
ional Institute of Allergy and Infectious Diseases Mycoses Study
roup (EORTC/MSG) in the revised 2008 version, although fre-
uently with additional, heterogeneous modifications or extensions
o cover non-hematological populations. Of note, despite the im-
ortant confounding effect of this heterogeneity, an almost con-
tant pattern was that of a reduced sensitivity of serum GM com-
ared to BALF GM ( Table 2 ). 
The available evidence on the diagnostic performance of lab-
ratory tests other than GM, i.e., respiratory cultures, (1,3)- β- D -
lucan (BDG), Aspergillus lateral-flow device (LFD), and polymerase
hain reaction (PCR), 15 , 16 , 18 , 19 , 23 , 26–29 is reported in detail in Table
 . Similar to what observed for GM, there was an important het-
rogeneity across studies in terms of population, reference defini-
ions, and positivity criteria, which makes it difficult to firmly de-ict the diagnostic performance of the various tests, with the ex-
eption of a few general patterns such as the low sensitivity of res-
iratory cultures and the suboptimal specificity of BDG. 
Finally, only one study evaluating the diagnostic performance
f radiology features met inclusion criteria ( Table 4 ). 30 The study
opulation was composed of non-hematological, non-SOT patients
ith chronic obstructive pulmonary disease. It is worth noting the
ow sensitivity ( < 25%) of classical radiology signs of IPA in hema-
ological populations (halo sign and air crescent/cavity). 
isk of bias 
The risk of bias in included studies is shown in Fig. 2 . Overall,
/19 (26%), 13/19 (68%), and 1/19 (5%) studies had a risk of bias of
 3, 3–4, and > 4 points according to the scoring system designed
or the project. 
iscussion 
The objective of this systematic review was to provide a qual-
tative, structured evaluation of the available evidence on the di-
gnostic performance of existing IA clinical definitions and/or lab-
ratory/radiology tests in critically ill, adult patients. 12 IPA was
he only form of IA for which evidence was available. In addi-
ion, we found an important heterogeneity across studies in terms
f population, prevalence, used reference definitions for IPA, (non-
tandardized) ad hoc variations of reference definitions, and cor-
ections of incorporation biases 31 ). The absence of proven diagno-
is as reference in most cases was also a major factor hampering
omparisons between studies. 
Another critical aspect to note is the far more frequent use of
eference definitions developed for other patient populations (e.g.,
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Table 1 
Studies assessing the performance of existing definitions and laboratory tests for the diagnosis IPA in critically ill patients with histology (biopsy/autopsy) as reference. 
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BALF, bronchoalveolar lavage fluid; CI, confidence intervals; DOR, diagnostic odds ratio; GM, galactomannan; ICU, intensive care unit; IPA, invasive pulmonary aspergillosis; 
LR −, negative likelihood ratio; LR + , positive likelihood ratio; NPV, negative predictive value; OD, optical density; PPV, positive predictive value. 
a Diagnostic performance parameters and 95% CI calculated for the present systematic review from data included in the original publication. With regard to the diagnostic 
performance of existing definitions, it refers to “probable cases” and “putative cases” in Vandewoude and Blot studies, respectively, with histology as reference. 
b Number of proven diagnosis/Number of patients with available biopsy/autopsy results. 





































t  EORCT/MSG 2008 6 ) rather than definitions specifically developed
for non-immunocompromised, critically-ill patients. Still, some im-
portant general patterns stem from our review: ( i ) for critically ill
patients with an Aspergillus -positive respiratory culture, the AspICU
definition showed encouraging sensitivity and specificity in those
few studies with histology/autopsy as reference ( Table 1 ); ( ii ) most
evidence regarding the diagnostic performance of laboratory tests
investigated the role of GM, with studies almost consistently in-
dicating a better performance of BALF GM than serum GM, espe-
cially in terms of sensitivity; ( iii ) generally, both serum and BALF
BDG showed suboptimal specificity for IPA; ( iv ) despite the paucity
of representative studies meeting the inclusion criteria, a general
pattern of reduced sensitivity for respiratory tract cultures and for
classical radiological signs of IPA as seen in hematological patients
was observed in this patient population. With regard to Aspergillus
LFD and PCR, there is limited available evidence to support general
conclusions. 
This systematic review aimed to provide the FUNDICU panel
with the available direct evidence in the population targeted byhe project: non-hematological patients in ICU; in next steps of
he project the panel of experts will also consider the existing,
ide literature on the performance of existing definitions, labora-
ory tests, and radiology in classical populations (e.g., hematologi-
al patients), including the recently released revision and update of
he IFD consensus definitions from EORTC/MSG. 8 Indeed, indirect
vidence will remain very helpful to draft some of the FUNDICU
efinitions, especially those involving the role of tests with cur-
ently limited direct evidence in the target population. Of note, in
valuating and balancing the available literature, the present as-
essment will also bring the attention of the panel to the fact that,
lthough ultimately only 5% of the papers were at high risk of bias,
his risk remained moderate in most included studies, and was low
nly in 26% of them. 
Finally, the present structured synthesis will inform panel dis-
ussions on other crucial aspects to be resolved: (i) whether or
ot including – and how to define – the “possible IPA” category
n critically ill patients; (ii) if specific radiological signs or labora-
ory tests should be considered, and if so, how should they influ-
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Table 2 
Studies assessing the performance of serum and bronchoalveolar fluid galactomannan for the diagnosis of IPA in critically ill patients with existing definitions as reference. 
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Table 2 
( continued ) 
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Table 2 
( continued ) 
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IPA prevalence e 
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Table 2 
( continued ) 





Type of IPA d 
IPA prevalence e 














(95% CI) Population 
Torelli et al., 
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pneumonia and at 
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at least 3 days of 
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Table 2 
( continued ) 





Type of IPA d 
IPA prevalence e 














(95% CI) Population 




















































ICU patients with 
clinical suspicion 



























































Zhang et al., 








factors present in 





and BALF GM 
testing in the 





















Fortun et al., 



















or COPD patients 
who underwent 
BALF GM testing in 
the suspicion of 
IPA 














Not calculated COPD patients 








































Not calculated Other patients 


























(continued on next page) 
140 M. Bassetti, D.R. Giacobbe and C. Grecchi et al. / Journal of Infection 81 (2020) 131–146 
Table 2 
( continued ) 





Type of IPA d 
IPA prevalence e 














(95% CI) Population 
Bellanger et 
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[61.5%]). Patients 
from ICU tested for 
GM in BALF 
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BALF, bronchoalveolar lavage fluid; CI, confidence intervals; COPD, chronic obstructive pulmonary disease; DOR, diagnostic odds ratio; EORTC/MSG, European Organization 
for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group; GM, 
galactomannan; HIV, human immunodeficiency virus; ICU, intensive care unit; IPA, invasive pulmonary aspergillosis; MV, mechanical ventilation; NA, not available; LR-, 
negative likelihood ratio; LR + , positive likelihood ratio; NPV, negative predictive value; OD, optical density; PCR, polymerase chain reaction; PPV, positive predictive value. 
a Diagnostic performance parameters and 95% CI calculated for the present systematic review from data included in the original publication. 
b Diagnostic performance parameters and 95% CI directly available in the original publication are presented (slightly different from those recalculated from the estimated 
numerator and denominator of the reference; data not shown). 
c Diagnostic performance parameters and 95% CI partly available in the original publication and partly calculated for this systematic review from data included in the 
original publication. 
d Type of IA defining the reference positivity (e.g., proven/probable = proven and probable classified as IPA vs. possible and other patients classified as non-IPA, 
proven/probable/possible = proven and probable and possible classified as IPA vs. other patients classified as non-IPA). 
e Number of IPA patients according to the reference positivity (see d )/Number of IPA patients plus non-IPA patients. 
f Detailed description of IPA categorization according to existing definitions is available in the Supplementary material. 
Table 3 
Studies assessing the performance of laboratory tests other than galactomannan for the diagnosis of IPA in critically ill patients with existing definitions as reference. 
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Table 3 
( continued ) 
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Table 3 
( continued ) 
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Table 3 
( continued ) 
Diagnostic performance of BALF LFD 
Study Design timeline 
reference f 
Type of IA d 
IA prevalence e 














(95% CI) Population 
Eigl et al., 






















ICU patients, of 
whom 13% were 
hematological, 
with clinical 
suspicion of IPA 
(see the original 
publication for 
details) 
Diagnostic performance of serum PCR 
Study 
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Design timeline 
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IPA prevalence e 
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or physical finding 
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Table 3 
( continued ) 
Diagnostic performance of BALF PCR 
Study 
type of PCR Design timeline 
reference f 
Type of IPA d 
IPA prevalence e 
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with fever lasting 
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BALF, bronchoalveolar lavage fluid; BDG, (1,3)- β- D -glucan; CI, confidence intervals; COPD, chronic obstructive pulmonary disease; DOR, diagnostic odds ratio; EORTC/MSG, 
European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases 
Mycoses Study Group; GM, galactomannan; HIV, human immunodeficiency virus; ICU, intensive care unit; IPA, invasive pulmonary aspergillosis; LRT, lower respiratory tract; 
MV, mechanical ventilation; NA, not available; LFD, lateral-flow device; LR-, negative likelihood ratio; LR + , positive likelihood ratio; NPV, negative predictive value; OD, 
optical density; PCR, polymerase chain reaction; PPV, positive predictive value; URT, upper respiratory tract. 
a Diagnostic performance parameters and 95% CI directly available in the original publication are presented (slightly different from those recalculated from the estimated 
numerator and denominator of the reference; data not shown). 
b Diagnostic performance parameters and 95% CI partly available in the original publication and partly calculated for this systematic review from data included in the 
original publication. 
c Diagnostic performance parameters and 95% CI calculated for the present systematic review from data included in the original publication. 
d Type of IA defining the reference positivity (e.g., proven/probable = proven and probable classified as IPA vs. possible and other patients classified as non-IPA, 
proven/probable/possible = proven and probable and possible classified as IPA vs. other patients classified as non-IPA). 
e Number of IPA patients according to the reference positivity (see d )/Number of IPA patients plus non-IPA patients. 
f Detailed description of IPA categorization according to existing definitions is available in the supplementary material. 
Table 4 
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ATB, Aspergillus tracheobronchitis; CI, confidence intervals; COPD, chronic obstructive pulmonary disease; CT, computerized tomography; DOR, diagnostic odds ratio; 
EORTC/MSG, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infec- 
tious Diseases Mycoses Study Group; IPA, invasive pulmonary aspergillosis; LR-, negative likelihood ratio; LR + , positive likelihood ratio; NPV, negative predictive value; PPV, 
positive predictive value; SOT, solid organ transplantation. 
a Diagnostic performance parameters and 95% CI partly available in the original publication and partly calculated for this systematic review from data included in the 
original publication. 
b Type of IPA defining the reference positivity (e.g., proven/probable = proven and probable classified as IPA vs. possible and other patients classified as non-IPA, 
proven/probable/possible = proven and probable and possible classified as IPA vs. other patients classified as non-IPA). 
c Number of IPA patients according to the reference positivity (see b )/Number of IPA patients plus non-IPA patients. 
d Detailed description of IPA categorization according to existing definitions is available in the Supplementary material. 
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Fig. 2. Risk of bias in included studies. 










































nce both categorization and diagnostic algorithms; (iii) whether
r not considering a “putative IPA” category 9 ; (iv) whether or not
xpanding the newly developed definitions to specific types of crit-
cally ill patients outside ICU (i.e., improving precision in defining
he target population); (v) whether or not considering inclusion of
pecific definitions for forms of IA other than IPA, in the absence
f pertinent evidence in this population. 
In conclusion, sufficient data for evaluating the performance of
xisting definitions and laboratory tests for the diagnosis of IA in
ritically ill patients is available only for IPA. With regard to exist-
ng definitions, only the AspICU criteria were evaluated against his-
ology/autopsy as reference, showing a promising diagnostic per-
ormance but based on small samples and applicable only to pa-
ients with positive respiratory cultures. Despite a wide hetero-
eneity in populations and employed reference, studies on labo-
atory tests consistently indicated a better diagnostic performance
f BALF GM than serum GM, and a suboptimal specificity of BALF
nd serum BDG. 
eclaration of Competing Interest 
Outside the submitted work, MB has received funding for scien-
ific advisory boards, travel and speaker honoraria from Angelini,
stellas, AstraZeneca, Basilea, Bayer, BioMérieux, Cidara, Correvio,
ubist, Menarini, Molteni, MSD, Nabriva, Paratek, Pfizer, Roche, Sh-onogi, Tetraphase, Thermo Fisher, and The Medicine Company.
RG reports personal fees from Stepstone Pharma GmbH and an
nconditional grant from MSD Italia. The other authors have no
onflicts of interest to disclose. 
unding 
The present project did not require additional funding from
outine research activities. Costs for open access publications will
e covered by research funds of the main authors. 
upplementary materials 
Supplementary material associated with this article can be
ound, in the online version, at doi:10.1016/j.jinf.2020.03.065 . 
eferences 
1. Bassetti M , Bouza E . Invasive mould infections in the ICU setting: complexities
and solutions. J Antimicrob Chemother 2017; 72 :i39–47 . 
2. Lamoth F , Calandra T . Early diagnosis of invasive mould infections and disease.
J Antimicrob Chemother 2017; 72 :i19–28 . 
3. Maschmeyer G , Haas A , Cornely OA . Invasive aspergillosis: epidemiol-
ogy, diagnosis and management in immunocompromised patients. Drugs
2007; 67 :1567–601 . 
4. Taccone FS , Van den Abeele AM , Bulpa P , Misset B , Meersseman W , Cardoso T ,
et al. Epidemiology of invasive aspergillosis in critically ill patients: clinical pre-
sentation, underlying conditions, and outcomes. Crit Care 2015; 19 :7 . 







































































5. Ascioglu S , Rex JH , de Pauw B , Bennett JE , Bille J , Crokaert F , et al. Defining
opportunistic invasive fungal infections in immunocompromised patients with
cancer and hematopoietic stem cell transplants: an international consensus. Clin
Infect Dis 2002; 34 :7–14 . 
6. De Pauw B , Walsh TJ , Donnelly JP , Stevens DA , Edwards JE , Calandra T , et al. Re-
vised definitions of invasive fungal disease from the European Organization for
Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group
and the National Institute of Allergy and Infectious Diseases Mycoses Study
Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46 :1813–21 . 
7. Husain S , Mooney ML , Danziger-Isakov L , Mattner F , Singh N , Avery R , et al. A
2010 working formulation for the standardization of definitions of infections in
cardiothoracic transplant recipients. J Heart Lung Transpl 2011; 30 :361–74 . 
8. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al.
Revision and Update of the Consensus Definitions of Invasive Fungal Disease
From the European Organization for Research and Treatment of Cancer and the
Mycoses Study Group Education and Research Consortium. Clin Infect Dis 2019.
doi: 10.1093/cid/ciz1008 . 
9. Blot SI , Taccone FS , Van den Abeele AM , Bulpa P , Meersseman W , Brusselaers N ,
et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in criti-
cally ill patients. Am J Respir Crit Care Med 2012; 186 :56–64 . 
10. Bulpa P , Dive A , Sibille Y . Invasive pulmonary aspergillosis in patients with
chronic obstructive pulmonary disease. Eur Respir J 2007; 30 :782–800 . 
11. Vandewoude KH , Blot SI , Depuydt P , Benoit D , Temmerman W , Colardyn F ,
et al. Clinical relevance of Aspergillus isolation from respiratory tract samples
in critically ill patients. Crit Care 2006; 10 :R31 . 
12. Bassetti M , Scudeller L , Giacobbe DR , Lamoth F , Righi E , Zuccaro V , et al. De-
veloping definitions for invasive fungal diseases in critically ill adult patients
in intensive care units. Protocol of the FUNgal infections Definitions in ICU pa-
tients (FUNDICU) project. Mycoses 2019; 62 :310–19 . 
13. Moher D , Liberati A , Tetzlaff J , Altman DG , Group P . Preferred reporting items
for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med
20 09; 6 :e10 0 0 097 . 
14. Meersseman W , Lagrou K , Maertens J , Wilmer A , Hermans G , Vanderschueren S ,
et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnos-
ing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med
2008; 177 :27–34 . 
15. Acosta J , Catalan M , del Palacio-Perez-Medel A , Lora D , Montejo JC , Cuetara MS ,
et al. A prospective comparison of galactomannan in bronchoalveolar lavage
fluid for the diagnosis of pulmonary invasive aspergillosis in medical patients
under intensive care: comparison with the diagnostic performance of galac-
tomannan and of (1–>3)-beta-D-glucan chromogenic assay in serum samples.
Clin Microbiol Infect 2011; 17 :1053–60 . 
16. Fortun J , Martin-Davila P , Gomez Garcia de la Pedrosa E , Silva JT , Garci-
a-Rodriguez J , Benito D , et al. Galactomannan in bronchoalveolar lavage fluid
for diagnosis of invasive aspergillosis in non-hematological patients. J Infect
2016; 72 :738–44 . 
17. Guinea J , Jensen J , Pelaez T , Gijon P , Alonso R , Rivera M , et al. Value of a single
galactomannan determination (Platelia) for the diagnosis of invasive aspergillo-
sis in non-hematological patients with clinical isolation of Aspergillus spp. Med
Mycol 2008; 46 :575–9 . 18. He H , Ding L , Sun B , Li F , Zhan Q . Role of galactomannan determinations in
bronchoalveolar lavage fluid samples from critically ill patients with chronic ob-
structive pulmonary disease for the diagnosis of invasive pulmonary aspergillo-
sis: a prospective study. Crit Care 2012; 16 :R138 . 
19. Imbert S , Gauthier L , Joly I , Brossas JY , Uzunov M , Touafek F , et al. As-
pergillus PCR in serum for the diagnosis, follow-up and prognosis of invasive
aspergillosis in neutropenic and nonneutropenic patients. Clin Microbiol Infect
2016; 22 :e561–8 562 . 
20. Ku NS , Han SH , Choi JY , Kim SB , Kim HW , Jeong SJ , et al. Diagnostic value of
the serum galactomannan assay for invasive aspergillosis: it is less useful in
non-haematological patients. Scand J Infect Dis 2012; 44 :600–4 . 
21. Lai CC , Hsu HL , Lee LN , Hsueh PR . Assessment of Platelia Aspergillus enzyme
immunoassay for the diagnosis of invasive aspergillosis. J Microbiol Immunol In-
fect 2007; 40 :148–53 . 
2. Park SY , Lee SO , Choi SH , Sung H , Kim MN , Choi CM , et al. Aspergillus galac-
tomannan antigen assay in bronchoalveolar lavage fluid for diagnosis of invasive
pulmonary aspergillosis. J Infect 2010; 61 :492–8 . 
3. Zhang S , Wang S , Wan Z , Li R , Yu J . The diagnosis of invasive and noninvasive
pulmonary aspergillosis by serum and bronchoalveolar lavage fluid galactoman-
nan assay. Biomed Res Int 2015; 2015 :943691 . 
24. Bellanger AP , Gbaguidi-Haore H , Tatoyan N , Berceanu A , Scherer E , Mil-
lon L . Local retrospective analysis of galactomannan cut-off values in bron-
choalveolar lavage fluids for diagnosis of invasive aspergillosis. Folia Microbiol
2018; 63 :757–61 . 
5. Khodavaisy S , Hedayati MT , Alialy M , Habibi MR , Badali H . Detection of galac-
tomannan in bronchoalveolar lavage of the intensive care unit patients at risk
for invasive aspergillosis. Curr Med Mycol 2015; 1 :12–17 . 
26. Prattes J , Flick H , Pruller F , Koidl C , Raggam RB , Palfner M , et al. Novel tests
for diagnosis of invasive aspergillosis in patients with underlying respiratory
diseases. Am J Respir Crit Care Med 2014; 190 :922–9 . 
27. Torelli R , Sanguinetti M , Moody A , Pagano L , Caira M , De Carolis E , et al. Diagno-
sis of invasive aspergillosis by a commercial real-time PCR assay for Aspergillus
DNA in bronchoalveolar lavage fluid samples from high-risk patients compared
to a galactomannan enzyme immunoassay. J Clin Microbiol 2011; 49 :4273–8 . 
8. Eigl S , Prattes J , Lackner M , Willinger B , Spiess B , Reinwald M , et al. Multicen-
ter evaluation of a lateral-flow device test for diagnosing invasive pulmonary
aspergillosis in ICU patients. Crit Care 2015; 19 :178 . 
9. Orsi CF , Bettua C , Pini P , Venturelli C , La Regina A , Morace G , et al. Detection of
Pneumocystis jirovecii and Aspergillus spp. DNa in bronchoalveolar lavage fluids
by commercial real-time PCr assays: comparison with conventional diagnostic
tests. New Microbiol 2015; 38 :75–84 . 
30. Huang L , He H , Ding Y , Jin J , Zhan Q . Values of radiological examinations for
the diagnosis and prognosis of invasive bronchial-pulmonary aspergillosis in
critically ill patients with chronic obstructive pulmonary diseases. Clin Respir
J 2018; 12 :499–509 . 
31. Pfeiffer CD , Fine JP , Safdar N . Diagnosis of invasive aspergillosis using a galac-
tomannan assay: a meta-analysis. Clin Infect Dis 2006; 42 :1417–27 . 
